105 related articles for article (PubMed ID: 21561771)
1. Discovery of novel tetracyclic compounds as anaplastic lymphoma kinase inhibitors.
Kinoshita K; Ono Y; Emura T; Asoh K; Furuichi N; Ito T; Kawada H; Tanaka S; Morikami K; Tsukaguchi T; Sakamoto H; Tsukuda T; Oikawa N
Bioorg Med Chem Lett; 2011 Jun; 21(12):3788-93. PubMed ID: 21561771
[TBL] [Abstract][Full Text] [Related]
2. 9-substituted 6,6-dimethyl-11-oxo-6,11-dihydro-5H-benzo[b]carbazoles as highly selective and potent anaplastic lymphoma kinase inhibitors.
Kinoshita K; Kobayashi T; Asoh K; Furuichi N; Ito T; Kawada H; Hara S; Ohwada J; Hattori K; Miyagi T; Hong WS; Park MJ; Takanashi K; Tsukaguchi T; Sakamoto H; Tsukuda T; Oikawa N
J Med Chem; 2011 Sep; 54(18):6286-94. PubMed ID: 21823617
[TBL] [Abstract][Full Text] [Related]
3. Methanesulfonamido-cyclohexylamine derivatives of 2,4-diaminopyrimidine as potent ALK inhibitors.
Zificsak CA; Theroff JP; Aimone LD; Angeles TS; Albom MS; Cheng M; Mesaros EF; Ott GR; Quail MR; Underiner TL; Wan W; Dorsey BD
Bioorg Med Chem Lett; 2011 Jul; 21(13):3877-80. PubMed ID: 21632243
[TBL] [Abstract][Full Text] [Related]
4. The discovery and optimization of a novel class of potent, selective, and orally bioavailable anaplastic lymphoma kinase (ALK) inhibitors with potential utility for the treatment of cancer.
Lewis RT; Bode CM; Choquette DM; Potashman M; Romero K; Stellwagen JC; Teffera Y; Moore E; Whittington DA; Chen H; Epstein LF; Emkey R; Andrews PS; Yu VL; Saffran DC; Xu M; Drew A; Merkel P; Szilvassy S; Brake RL
J Med Chem; 2012 Jul; 55(14):6523-40. PubMed ID: 22734674
[TBL] [Abstract][Full Text] [Related]
5. Design, synthesis, and biological activity of urea derivatives as anaplastic lymphoma kinase inhibitors.
af Gennäs GB; Mologni L; Ahmed S; Rajaratnam M; Marin O; Lindholm N; Viltadi M; Gambacorti-Passerini C; Scapozza L; Yli-Kauhaluoma J
ChemMedChem; 2011 Sep; 6(9):1680-92. PubMed ID: 21721129
[TBL] [Abstract][Full Text] [Related]
6. Discovery of 2-arylamino-4-(1-methyl-3-isopropylsulfonyl-4-pyrazol-amino)pyrimidines as potent anaplastic lymphoma kinase (ALK) inhibitors.
Zhang P; Dong J; Zhong B; Zhang D; Jin C; Meng X; Sun D; Xu X; Zhou Y; Liang Z; Ji M; Li H; Xu T; Song G; Zhang L; Chen G; Yuan H; Shih J; Zhang R; Hou G; Jin Y; Yang Q
Bioorg Med Chem Lett; 2015 Sep; 25(17):3738-43. PubMed ID: 26130408
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic/pharmacodynamic modeling of crizotinib for anaplastic lymphoma kinase inhibition and antitumor efficacy in human tumor xenograft mouse models.
Yamazaki S; Vicini P; Shen Z; Zou HY; Lee J; Li Q; Christensen JG; Smith BJ; Shetty B
J Pharmacol Exp Ther; 2012 Mar; 340(3):549-57. PubMed ID: 22129595
[TBL] [Abstract][Full Text] [Related]
8. Identification of novel anaplastic lymphoma kinase (ALK) inhibitors using a common feature pharmacophore model derived from known ligands crystallized with ALK.
Xie HZ; Lan H; Pan YL; Zou J; Wang ZR; Li LL; Huang Q; Zhang H; Yang SY
Chem Biol Drug Des; 2013 Feb; 81(2):175-84. PubMed ID: 23107363
[TBL] [Abstract][Full Text] [Related]
9. N-(4-(6,7-Disubstituted-quinolin-4-yloxy)-3-fluorophenyl)-2-oxo-3-phenylimidazolidine-1-carboxamides: a novel series of dual c-Met/VEGFR2 receptor tyrosine kinase inhibitors.
Mannion M; Raeppel S; Claridge S; Zhou N; Saavedra O; Isakovic L; Zhan L; Gaudette F; Raeppel F; Déziel R; Beaulieu N; Nguyen H; Chute I; Beaulieu C; Dupont I; Robert MF; Lefebvre S; Dubay M; Rahil J; Wang J; Ste-Croix H; Robert Macleod A; Besterman JM; Vaisburg A
Bioorg Med Chem Lett; 2009 Dec; 19(23):6552-6. PubMed ID: 19854051
[TBL] [Abstract][Full Text] [Related]
10. Antitumor activity of pyridoisoquinoline derivatives F91873 and F91874, novel multikinase inhibitors with activity against the anaplastic lymphoma kinase.
Kruczynski A; Mayer P; Marchand A; Vispé S; Fournier E; Annereau JP; Brel V; Barret JM; Delsol G; Imbert T; Fahy J; Bailly C
Anticancer Drugs; 2009 Jun; 20(5):364-72. PubMed ID: 19322071
[TBL] [Abstract][Full Text] [Related]
11. Rapid development of piperidine carboxamides as potent and selective anaplastic lymphoma kinase inhibitors.
Bryan MC; Whittington DA; Doherty EM; Falsey JR; Cheng AC; Emkey R; Brake RL; Lewis RT
J Med Chem; 2012 Feb; 55(4):1698-705. PubMed ID: 22263917
[TBL] [Abstract][Full Text] [Related]
12. Targeting anaplastic lymphoma kinase in lung cancer.
Shaw AT; Solomon B
Clin Cancer Res; 2011 Apr; 17(8):2081-6. PubMed ID: 21288922
[TBL] [Abstract][Full Text] [Related]
13. Pyrazolone-based anaplastic lymphoma kinase (ALK) inhibitors: control of selectivity by a benzyloxy group.
Tripathy R; McHugh RJ; Ghose AK; Ott GR; Angeles TS; Albom MS; Huang Z; Aimone LD; Cheng M; Dorsey BD
Bioorg Med Chem Lett; 2011 Dec; 21(24):7261-4. PubMed ID: 22061645
[TBL] [Abstract][Full Text] [Related]
14. Discovery of (10R)-7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a macrocyclic inhibitor of anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1) with preclinical brain exposure and broad-spectrum potency against ALK-resistant mutations.
Johnson TW; Richardson PF; Bailey S; Brooun A; Burke BJ; Collins MR; Cui JJ; Deal JG; Deng YL; Dinh D; Engstrom LD; He M; Hoffman J; Hoffman RL; Huang Q; Kania RS; Kath JC; Lam H; Lam JL; Le PT; Lingardo L; Liu W; McTigue M; Palmer CL; Sach NW; Smeal T; Smith GL; Stewart AE; Timofeevski S; Zhu H; Zhu J; Zou HY; Edwards MP
J Med Chem; 2014 Jun; 57(11):4720-44. PubMed ID: 24819116
[TBL] [Abstract][Full Text] [Related]
15. Development of anaplastic lymphoma kinase (ALK) small-molecule inhibitors for cancer therapy.
Li R; Morris SW
Med Res Rev; 2008 May; 28(3):372-412. PubMed ID: 17694547
[TBL] [Abstract][Full Text] [Related]
16. Design and synthesis of a highly selective, orally active and potent anaplastic lymphoma kinase inhibitor (CH5424802).
Kinoshita K; Asoh K; Furuichi N; Ito T; Kawada H; Hara S; Ohwada J; Miyagi T; Kobayashi T; Takanashi K; Tsukaguchi T; Sakamoto H; Tsukuda T; Oikawa N
Bioorg Med Chem; 2012 Feb; 20(3):1271-80. PubMed ID: 22225917
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and structure-activity relationships of 1,2,3,4-tetrahydropyrido[2,3-b]pyrazines as potent and selective inhibitors of the anaplastic lymphoma kinase.
Milkiewicz KL; Weinberg LR; Albom MS; Angeles TS; Cheng M; Ghose AK; Roemmele RC; Theroff JP; Underiner TL; Zificsak CA; Dorsey BD
Bioorg Med Chem; 2010 Jun; 18(12):4351-62. PubMed ID: 20483621
[TBL] [Abstract][Full Text] [Related]
18. Novel tetracyclic benzo[b]carbazolones as highly potent and orally bioavailable ALK inhibitors: design, synthesis, and structure-activity relationship study.
Jiang X; Zhou J; Ai J; Song Z; Peng X; Xing L; Xi Y; Guo J; Yao Q; Ding J; Geng M; Zhang A
Eur J Med Chem; 2015 Nov; 105():39-56. PubMed ID: 26476749
[TBL] [Abstract][Full Text] [Related]
19. Discovery of novel tetrahydroisoquinoline-containing pyrimidines as ALK inhibitors.
Achary R; Yun JI; Park CM; Mathi GR; Lee JY; Ha JD; Chae CH; Ahn S; Park CH; Lee CO; Hwang JY; Yun CS; Jung HJ; Cho SY; Kim HR; Kim P
Bioorg Med Chem; 2016 Jan; 24(2):207-19. PubMed ID: 26712094
[TBL] [Abstract][Full Text] [Related]
20. Design and synthesis of 5-aryl-pyridone-carboxamides as inhibitors of anaplastic lymphoma kinase.
Li R; Xue L; Zhu T; Jiang Q; Cui X; Yan Z; McGee D; Wang J; Gantla VR; Pickens JC; McGrath D; Chucholowski A; Morris SW; Webb TR
J Med Chem; 2006 Feb; 49(3):1006-15. PubMed ID: 16451066
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
